These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 16734724)
1. DNA damage and altered gene expression of enzymes for metabolism and DNA repair by tamoxifen and toremifene in the female rat liver. Hashiba M; Kasahara T; Kim SY; Shibutani S; Degawa M Cancer Sci; 2006 Jun; 97(6):468-77. PubMed ID: 16734724 [TBL] [Abstract][Full Text] [Related]
2. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Bartsch H; Phillips DH; Nair J; Hewer A; Meyberg-Solomeyer G; Grischke EM Carcinogenesis; 2000 Apr; 21(4):845-7. PubMed ID: 10753226 [TBL] [Abstract][Full Text] [Related]
3. Mechanism of lower genotoxicity of toremifene compared with tamoxifen. Shibutani S; Ravindernath A; Terashima I; Suzuki N; Laxmi YR; Kanno Y; Suzuki M; Apak TI; Sheng JJ; Duffel MW Cancer Res; 2001 May; 61(10):3925-31. PubMed ID: 11358807 [TBL] [Abstract][Full Text] [Related]
4. Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Li D; Dragan Y; Jordan VC; Wang M; Pitot HC Cancer Res; 1997 Apr; 57(8):1438-41. PubMed ID: 9108442 [TBL] [Abstract][Full Text] [Related]
5. Alpha-hydroxylation of tamoxifen and toremifene by human and rat cytochrome P450 3A subfamily enzymes. Kim SY; Suzuki N; Santosh Laxmi YR; Rieger R; Shibutani S Chem Res Toxicol; 2003 Sep; 16(9):1138-44. PubMed ID: 12971802 [TBL] [Abstract][Full Text] [Related]
6. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Hard GC; Iatropoulos MJ; Jordan K; Radi L; Kaltenberg OP; Imondi AR; Williams GM Cancer Res; 1993 Oct; 53(19):4534-41. PubMed ID: 8402624 [TBL] [Abstract][Full Text] [Related]
7. Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Montandon F; Williams GM Arch Toxicol; 1994; 68(4):272-5. PubMed ID: 8067901 [TBL] [Abstract][Full Text] [Related]
8. Comparative metabolic study between two selective estrogen receptor modulators, toremifene and tamoxifen, in human liver microsomes. Watanabe M; Watanabe N; Maruyama S; Kawashiro T Drug Metab Pharmacokinet; 2015 Oct; 30(5):325-33. PubMed ID: 26423799 [TBL] [Abstract][Full Text] [Related]
9. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats. Dragan YP; Shimel RJ; Bahnub N; Sattler G; Vaughan JR; Jordan VC; Pitot HC Toxicol Sci; 1998 Jun; 43(2):129-38. PubMed ID: 9710954 [TBL] [Abstract][Full Text] [Related]
10. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Randerath K; Moorthy B; Mabon N; Sriram P Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037 [TBL] [Abstract][Full Text] [Related]
12. The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-inducible hepatic proteins and estrogen receptor proteins in female rats. Kendall ME; Rose DP Toxicol Appl Pharmacol; 1992 May; 114(1):127-31. PubMed ID: 1533964 [TBL] [Abstract][Full Text] [Related]
13. Role and pharmacologic significance of cytochrome P-450 2D6 in oxidative metabolism of toremifene and tamoxifen. Kim J; Coss CC; Barrett CM; Mohler ML; Bohl CE; Li CM; He Y; Veverka KA; Dalton JT Int J Cancer; 2013 Mar; 132(6):1475-85. PubMed ID: 22915089 [TBL] [Abstract][Full Text] [Related]
14. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Ahotupa M; Hirsimäki P; Pärssinen R; Mäntylä E Carcinogenesis; 1994 May; 15(5):863-8. PubMed ID: 8200088 [TBL] [Abstract][Full Text] [Related]
15. DNA adduct formation in the livers of female Sprague-Dawley rats treated with toremifene or alpha-hydroxytoremifene. Gamboa da Costa G; Pereira PC; Churchwell MI; Beland FA; Marques MM Chem Res Toxicol; 2007 Feb; 20(2):300-10. PubMed ID: 17261033 [TBL] [Abstract][Full Text] [Related]
16. Microsomal and peroxidase activation of 4-hydroxy-tamoxifen to form DNA adducts: comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Pathak DN; Pongracz K; Bodell WJ Carcinogenesis; 1995 Jan; 16(1):11-5. PubMed ID: 7834794 [TBL] [Abstract][Full Text] [Related]
17. DNA adducts caused by tamoxifen and toremifene in human microsomal system and lymphocytes in vitro. Hemminki K; Widlak P; Hou SM Carcinogenesis; 1995 Jul; 16(7):1661-4. PubMed ID: 7614704 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization and semi-quantitation of hepatic tamoxifen-DNA adducts in rats exposed orally to tamoxifen. Divi RL; Dragan YP; Pitot HC; Poirier MC Carcinogenesis; 2001 Oct; 22(10):1693-9. PubMed ID: 11577011 [TBL] [Abstract][Full Text] [Related]
19. Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Hellmann-Blumberg U; Taras TL; Wurz GT; DeGregorio MW Breast Cancer Res Treat; 2000 Mar; 60(1):63-70. PubMed ID: 10845810 [TBL] [Abstract][Full Text] [Related]
20. Activation of 4-hydroxytamoxifen and the tamoxifen derivative metabolite E by uterine peroxidase to form DNA adducts: comparison with DNA adducts formed in the uterus of Sprague-Dawley rats treated with tamoxifen. Pathak DN; Pongracz K; Bodell WJ Carcinogenesis; 1996 Sep; 17(9):1785-90. PubMed ID: 8824496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]